<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697188</url>
  </required_header>
  <id_info>
    <org_study_id>CLAR-07004</org_study_id>
    <nct_id>NCT02697188</nct_id>
  </id_info>
  <brief_title>Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men</brief_title>
  <official_title>Phase IIa, Pilot, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clarus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the serum pharmacokinetic profile for two oral formulations of T-esters (one TE and
      one TU) administered once -(QD) and twice-daily (BID) to hypogonadal men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five period cross-over study in which subjects received a single day of dosing in each
      period. Dosing was either QD or BID with one of two T esters (T-enanthate (TE) or
      T-undecanoate (TU)). Dosing was within 5 minutes of meals (breakfast and for BID dosing
      dinner). There was a minimum of a 5-day washout between periods. Subjects were hypogonadal
      men.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Serum Testosterone Cavg</measure>
    <time_frame>Concentrations at -0.5, 0, 1, 2, 4, 8, 12, 13, 14, 16, 20, 24 and 34 hours post dose</time_frame>
    <description>The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Serum Dihydrotestosterone Cmax</measure>
    <time_frame>24 hours post-dose in each period</time_frame>
    <description>The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone undecanoate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone enanthate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone undecanoate</intervention_name>
    <description>Single-day dose as QD or BID for 3 of 5 crossover periods</description>
    <arm_group_label>Testosterone undecanoate</arm_group_label>
    <other_name>TU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone enanthate</intervention_name>
    <description>Single-day dose for 2 of 5 crossover periods</description>
    <arm_group_label>Testosterone enanthate</arm_group_label>
    <other_name>TE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male, ages 18 to 65 Serum total testosterone less than or equal to 250 ng/dL Naive to
        androgen replacement therapy Subject must be on stable doses of thyroid or adrenal
        replacement hormones for at least 14 days prior to enrollment

        Exclusion Criteria:

        Significant intercurrent disease of any type, in particular, liver, kidney or heart
        disease, uncontrolled diabetes mellitus or psychiatric illness. Patients with treated
        hyperlipidemia will not be excluded provided they have been stable on their lipid-lowering
        mediation for at least three months. For non-insulin dependent diabetic subjects, HbA1c&gt;9%.

        Abnormal prostate digital rectal examination, elevated PSA (serum PSA &gt;4ng/mL), AUA Sympton
        Score greater than or equal to 15 points, and a history or prostate cancer.

        Serum transaminases &gt;2X upper limit of normal (ULN) or serum bilirubin &gt;2.0 mg/dL.

        History of severe or multiple allergies, severe adverse drug reaction or leucopenia. Known
        hypersensitivity to lidocaine or all surgical dressings.

        History of abnormal bleeding tendencies. Oral, topical, or buccal T therapy within the
        previous week, or intramuscular T injection within the previous 4 week.

        Use of dietary supplements that may increase serum T, such as androstenedione or DHEA,
        within the previous 4 weeks.

        Know malabsorption syndrome and/or current treatment with oral lipase inhibitors, bile
        acid-binding resins, colestipol, fibric acid derivatives, gemfibrozil, and probucol.

        Smokers who are unable to refrain from smoking during confinement periods. History of, or
        current evidence of, abuse of alcohol or any drug substance. Poor compliers or those
        unlikely to attend. Receipt of any drug as part of a research study within 30 days of
        inital dose administration in this study.

        Blood donation (usually 550 mL) within the 12-week period before the initial study dose.

        Hematocrit less than 35%. Known clinical polycythemia or hematocrit greater than 50%.
        Current use of paroxetine and clomipramine, antiandrogens, estrogens, p450 enzyme inducers,
        or barbiturates.

        History of sleep apnea.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald S Swerdloff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherwyn Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>dgd Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>dgd Research, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <results_first_submitted>July 16, 2018</results_first_submitted>
  <results_first_submitted_qc>October 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2018</results_first_posted>
  <last_update_submitted>October 3, 2018</last_update_submitted>
  <last_update_submitted_qc>October 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>male hypogonadism</keyword>
  <keyword>low testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Cross over study with 5 periods. Twelve subjects enrolled and completed 5 crossover periods each.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Enanthate and Testosterone Undecanoate</title>
          <description>Testosterone Enanthate Periods 1 and 5 Single-day dose as QD Period 1 and BID Period 5 Testosterone Undecanoate: Single-day dose as QD Period 2 and BID Periods 3 and 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>TE Period 1 - 400 mg QD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>TU Period 2 – 200 mg QD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>TU Period 3 - 200 mg BID</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>TU Period 4 - 400 BID</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>TE Period 5 - 800 mg BID</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Enanthate and Testosterone Undecanoate</title>
          <description>Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose) Testosterone enanthate: Single-day dose for 2 of 5 crossover periods
Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose) Testosterone undecanoate: Single-day dose as QD or BID for 3 of 5 crossover periods</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="31" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Serum Testosterone Cavg</title>
        <description>The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.</description>
        <time_frame>Concentrations at -0.5, 0, 1, 2, 4, 8, 12, 13, 14, 16, 20, 24 and 34 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate and Testosterone Undecanoate</title>
            <description>Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
Testosterone enanthate: Single-day dose for 2 of 5 crossover periods Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
Testosterone undecanoate: Single-day dose as QD or BID for 3 of 5 crossover periods</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Testosterone Cavg</title>
          <description>The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TE Period 1 400 mg QD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293" spread="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TU Period 2 200 mg QD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TU Period 3 100 mg BID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" spread="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TU Period 4 200 mg BID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE Period 5 400 mg BID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316" spread="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Serum Dihydrotestosterone Cmax</title>
        <description>The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.</description>
        <time_frame>24 hours post-dose in each period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate and Testosterone Undecanoate</title>
            <description>Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
Testosterone enanthate: Single-day dose for 2 of 5 crossover periods Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
Testosterone undecanoate: Single-day dose as QD or BID for 3 of 5 crossover periods</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Serum Dihydrotestosterone Cmax</title>
          <description>The objective of the study was to determine the single day serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU formulation) administered once- and twice-daily to hypogonadal men.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TE Period 1 400 mg QD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" spread="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TU Period 2 200 mg QD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TU Period 3 100 mg BID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TU Period 4 200 mg BID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE Period 5 400 mg BID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127" spread="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects received doses on 5 dosing days spanning approximately 4 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Testosterone Enanthate 400 mg QD</title>
          <description>Period 1: Testosterone Enanthate 400 mg QD</description>
        </group>
        <group group_id="E2">
          <title>Testosterone Undecanoate 200 mg QD</title>
          <description>Period 2: Testosterone Undecanoate 200 mg QD</description>
        </group>
        <group group_id="E3">
          <title>Testosterone Undecanoate 100 mg BID</title>
          <description>Period 3: Testosterone Undecanoate 100 mg BID</description>
        </group>
        <group group_id="E4">
          <title>Testosterone Undecanoate 200 mg BID</title>
          <description>Period 4: Testosterone Undecanoate 200 mg BID</description>
        </group>
        <group group_id="E5">
          <title>Testosterone Enanthate 400 mg BID</title>
          <description>Period 5: Testosterone Enanthate 400 mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>anemia/low hemoglobin/ low hematocrit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>indigestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>frontal headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>lethargic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <description>runny nose/ sinus congestion/stuffy nose/ nasal congestion/ sneezing/ cough</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore Danoff, MD, PhD</name_or_title>
      <organization>Clarus Therapeutics</organization>
      <phone>847-562-4300 ext 212</phone>
      <email>tdanoff@clarustherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

